Ad Com thumbs down on Trevena's oliceridine

|By:, SA News Editor

In a close vote, the FDA's Anesthetic and Analgesic Drugs Advisory Committee voted 8-7 against approval for Trevena's (TRVN) pain med oliceridine for the proposed indication.

Nasdaq has yet to announced the resumption of trading.

Previously: Trevena shares halted pending outcome of Ad Com meeting (Oct. 11)

Subscribe for full text news in your inbox